Recombinant Human TMEFF2/Tomoregulin-2 His-tag Protein, CF

When Recombinant Human PDGF-AA (221-AA) is immobilized at 5.00 μg/mL (100 μL/well), Recombinant Human TMEFF2/Tomoregulin-2 His-tag Protein (Catalog # 11107-TF) binds with an ED50 of 0.750‑4.50 μg/mL.

2 μg/lane of Recombinant Human TMEFF2/Tomoregulin‑2 His-tag Protein (Catalog # 11107-TF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-66 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TMEFF2/Tomoregulin-2 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human PDGF-AA (Catalog # 221-AA) is immobilized at 5.00 μg/mL (100 μL/well), Recombinant Human TMEFF2/Tomoregulin-2 His-tag Protein binds with an ED₅₀ of 0.750-4.50 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human TMEFF2/Tomoregulin-2 protein
  Arg34-Val320, with a C-terminal 10-His tag
• Accession #: Q9UIK5.1
• N-terminal Sequence: Arg34
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity2
• Theoretical MW: 33 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 55-66 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TMEFF2/Tomoregulin-2 His-tag Protein, CF

• CT120.2
• HPP1member 2
• Hyperplastic polyposis protein 1
• TENB2
• TMEFF2
• Tomoregulin2
• Tomoregulin-2
• TPEFtomoregulin
• TR-2
• transmembrane protein TENB2
• transmembrane protein with EGF-like and two follistatin-like domains 2
• Transmembrane protein with EGF-like and two follistatin-like domains
• TRtomoregulin-2

Background

TMEFF2 (transmembrane protein with an EGF-like and two Follistatin-like domains 2), also known as Tomoregulin-2, is a type I transmembrane glycoprotein that contains two extracellular follistatin modules, an extracellular EGF-like domain, a transmembrane domain, and a short conserved cytoplasmic tail (1) Soluble extracellular domains of both TMEFF1 and 2 can be generated by proteolytic cleavage. TMEFF2 amino acid (aa) sequences are 98.9% identical for human and mouse orthologs (1). The differential methylation of TMEFF2 can be related to the response to therapy and survival outcomes of the stages of cancers such as breast, prostate, lung, bladder, colon and rectal, gallbladder, renal, oesophageal, cardiac, stomach/gastric, ovarian, multiple myeloma, glioblastoma, and mesothelioma. The range of tissue expression of TMEFF2 functions as a possible biomarker and/or therapeutic target (1). Studies showed that TMEFF2 binds and inhibits PDGF-AA (2, 3). It also inhibits the proliferation of DU145 and PC3 prostate cancer cell lines (4). The amyloid-b protein, its precursor AbPP, and amyloid- b proteins AbPOs also bind TMEFF2, suggesting a neuroprotective role on Alzheimer's disease (5). TMEFF2's diverse function includes metabolism, embryonic development, cytoskeletal binding, extracellular matrix binding, chromatin binding and interaction of RNA polymerase II with DNA (6), and neuronal development (7).

1. Masood, M. et al. (2020) Cancers 12:3862.
2. Lin, K. et al. (2011) PLoS ONE 6:e18608.
3. Huang, H. et al. (2017) Sci. Rep. 7:337.
4. Gery, S. et al. (2002) Oncogene 21:4739.
5. Hong, H.S. et al. (2015) Alzheimers Dis. 48:731.
6. Gao, L. et al. (2020) Life Sci. 243:116910.
7. Horie, M. et al. (2000) Genomics 67:146.

Bioinformatics

• Uniprot:
  • Q9UIK5.1()